Madrigal Pharmaceuticals Inc (MDGL) Stock Analysis
Verdict: WATCH (do not buy)
First-mover advantage in MASH with Rezdiffra drives top-line expansion toward 2027 profitability, offset by cash burn and executive selling.
Investment score: 59/100
Analysis as of
Is Madrigal Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
The model evaluates Madrigal Pharmaceuticals as a HOLD. First-mover dominance with Rezdiffra and multi-year revenue acceleration are tempered by elevated P/S multiples (9.67x) and ongoing operational cash burn.
7-factor investment score
- Valuation: 52/100 (weight 20%)
- Financial Health: 68/100 (weight 15%)
- Technical Momentum: 62/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 82/100 (weight 10%)
- Risk-Adjusted Return: 58/100 (weight 15%)
Madrigal Pharmaceuticals Inc opportunities and risks
What speaks for MDGL
- First-Mover Dominance in MASH Therapeutics
What speaks against MDGL
- Continued Cash Burn Prior to Net Profitability
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MDGL | n/a | 9.7x | n/a | 91.5% | -25.3% | -1.7% |
| EXEL | 17.6x | 6.0x | 13.9x | 96.5% | 35.3% | 8.0% |
| SMMT | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.9% |
| BBIO | n/a | 19.5x | n/a | 93.1% | -100.6% | -4.4% |
| BMRN | 173.4x | 3.7x | 41.7x | 75.5% | 2.1% | 5.8% |
| HALO | 30.9x | 7.8x | 20.9x | 78.2% | 24.9% | 6.2% |
| Peer median | 17.6x | 6.0x | 13.9x | 78.2% | 2.1% | 5.8% |
Frequently asked questions about Madrigal Pharmaceuticals Inc (MDGL)
Is MDGL stock a good investment?
The TradeMates model rates Madrigal Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 59/100. The model evaluates Madrigal Pharmaceuticals as a HOLD. First-mover dominance with Rezdiffra and multi-year revenue acceleration are tempered by elevated P/S multiples (9.67x) and ongoing operational cash burn. This is algorithmic model output, not personal investment advice.
Is MDGL stock a buy?
The TradeMates model verdict for MDGL is WATCH (do not buy) with an investment score of 59/100. Treat this as a model signal to review, not a personal buy recommendation.